非常早期药物流产的随机试验
Karin Brandell1, Tagrid Jar-Allah1, John Reynolds-Wright1
1From the Department of Women's and Children's Health, Division of Obstetrics and Gynecology (K.B., K.G.-D.), and the Department of Clinical Sciences at Danderyd Hospital (H.K.K.), Karolinska Institutet, and the Department of Obstetrics and Gynecology, Karolinska University Hospital (K.G.-D.), Stockholm, Södertälje Hospital, Södertälje (K.B.), the Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg (T.J.-A., H.H.), the Department of Obstetrics and Gynecology, Skåne University Hospital, Malmö (P.T.), the Department of Clinical Sciences, Lund University Faculty of Medicine, Lund (P.T.), the Department of Clinical Sciences, Obstetrics, and Gynecology, Umeå University, Umeå (M.B.), and Statisticon, Uppsala (J.B.) - all in Sweden; the Centre for Reproductive Health, Institute for Regeneration and Repair, University of Edinburgh, and Chalmers Centre, NHS Lothian - both in Edinburgh (J.R.-W., S.C.); the Departments of Obstetrics and Gynecology (F.G., J.K., O.H.) and General Practice and Primary Health Care (F.G.), University of Helsinki and Helsinki University Hospital, Helsinki, and the Division of Health and Social Services, Wellbeing Services County of Vantaa and Kerava, Vantaa (F.G.) - both in Finland; the Center for Research on Environment, Health, and Population Activities, Kathmandu (A.T.), and KIST Medical College Teaching Hospital, Lalitpur (H.T.) - both in Nepal; Family Planning Australia, Sydney Medical School, University of Sydney, and the School of Public Health, University of Technology Sydney - all in Sydney (C.B.); Women's Health, Auckland City Hospital, Auckland, New Zealand (K.S., G.G.); the Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway (M.L.); and the Department of Obstetrics and Gynecology, Copenhagen University Hospital Hvidovre, Hvidovre (M.M.K.), and the Hospital of Southern Jutland, Aabenraa (E.K.) - both in Denmark.
使用米费普里斯顿和米索普罗斯托尔的早期药物流产与标准治疗一样有效. 这项研究表明,在早期开始的药物堕胎中,完全堕胎率没有显著差异.
科学领域:
- 生殖健康 生殖健康
- 临床试验 临床试验
- 药理学 药理学是指药理学的学科.
背景情况:
- 使用米费普里斯顿和米索普罗斯托尔进行药物流产是一种安全有效的方法.
- 在非常早期的妊娠期 (超声波可视化之前) 疗效和安全性的证据有限.
研究的目的:
- 为了比较立即药物流产的疗效和安全性与未经证实的早期怀孕的标准延迟治疗.
- 为了确定早期开始的药物流产是否与标准护理无差.
主要方法:
- 进行了一项多中心,非劣势,随机对照试验.
- 参与者在超声波确认后接受了即时的药物流产或标准护理.
- 主要结局是完全堕胎,非劣势率为3.0个百分点.
主要成果:
- 完全堕胎发生在早期开始组的95.2%和标准组的95.3%中.
- 绝对差异为-0.1个百分点,符合非劣质标准.
- 宫外怀孕和严重不良事件是罕见的,在不同组之间是可比的.
结论:
- 在超声波确认子宫内怀孕之前开始的药物流产与标准延迟治疗无差.
- 早期开始的药物流产是管理早期怀孕的安全有效选择.
更多相关视频
05:33Author Spotlight: Alleviating Nausea and Vomiting in Pregnancy with Safe and Effective Auricular Acupuncture
Published on: August 4, 2023
03:01Author Spotlight: A Reproductive Hysteroscopy Approach for Complete Endometrial Polyp Removal and Enhanced Endometrial Receptivity
Published on: August 2, 2024
